Press release
Biliary Tract Cancers Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight
DelveInsight's, "Biliary Tract Cancers Pipeline Insight, 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers pipeline landscape. It covers the Biliary Tract Cancers pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Biliary Tract Cancers pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Biliary Tract Cancers Pipeline Report
• DelveInsight's Biliary Tract Cancers pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Biliary Tract Cancers treatment.
• The leading companies working in the Biliary Tract Cancers market include Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others.
• Promising Biliary Tract Cancers Pipeline Therapies in the various stages of development include M7824, SMT-NK inj.+Pembrolizumab, Durvalumab, mFOLFOX, ZKAB001 5mg/kg, Capecitabine, RC48-ADC, Atezolizumab, Bevacizumab, Lenvatinib, MRG003, Gemcitabine, Cisplatin, and others.
• November 2023: AstraZeneca announced a study of Phase 2 clinical trials for AZD5305, Durvalumab, Capecitabine, and Volrustomig. This Phase II, open-label, uncontrolled, multicentre study evaluating the efficacy and safety of Dato-DXd as monotherapy (MONO) and in combination with anticancer agents (COMBO) in various advanced solid tumour types. This study has a modular design, as such a master protocol with independent substudies enables simultaneous evaluation of the safety profile, recommended Phase II dose (RP2D), and efficacy of Dato-DXd in multiple disease populations and treatment combinations. This study will evaluate various solid tumour types, including endometrial cancer (Substudy 1), gastric cancer (Substudy 2), metastatic castration-resistant prostate cancer (mCRPC) (Substudy 3), ovarian cancer (Substudy 4), colorectal cancer (CRC) (Substudy 5), urothelial cancer (Substudy 6) and biliary tract cancer (Substudy 7) in the advanced or metastatic setting. Within each substudy, Dato-DXd will be evaluated as monotherapy (for all substudies except Substudy 2 (Gastric Cancer) and Substudy 6 (Urothelial Cancer) and in combination with approved or novel anticancer agents that may be active in the tumour type being evaluated (for all substudies except Substudy 7).
• November 2023: Bristol-Myers Squibb announced a study of Phase 1 & 2 clinical trials for BMS-986466, Adagrasib and Cetuximab. The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).
Request a sample and discover the recent advances in Biliary Tract Cancers Treatment Drugs @ Biliary Tract Cancers Pipeline Report- https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Biliary Tract Cancers pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Biliary Tract Cancers drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Biliary Tract Cancers clinical trial landscape.
Biliary Tract Cancers Overview
Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation.
Find out more about Biliary Tract Cancers Treatment Drugs @ Drugs for Biliary Tract Cancers Treatment- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Biliary Tract Cancers Emerging Drugs Profile
• MRG 002: Miracogen
• Disitamab vedotin: Yantai Rongchang Pharmaceutical
• Envafolimab: Alphamab Oncology
• DKN-01: Leap Therapeutics
Biliary Tract Cancers Pipeline Therapeutics Assessment
The Biliary Tract Cancers pipeline report proffers an integral view of the Biliary Tract Cancers emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
DelveInsight's Biliary Tract Cancers Pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Biliary Tract Cancers Pipeline Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Learn more about the emerging Biliary Tract Cancers Pipeline Therapies @ Biliary Tract Cancers Clinical Trials Assessment- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Biliary Tract Cancers Pipeline Report
• Coverage- Global
• Biliary Tract Cancers Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Biliary Tract Cancers Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others.
• Biliary Tract Cancers Pipeline Therapies- M7824, SMT-NK inj.+Pembrolizumab, Durvalumab, mFOLFOX, ZKAB001 5mg/kg, Capecitabine, RC48-ADC, Atezolizumab, Bevacizumab, Lenvatinib, MRG003, Gemcitabine, Cisplatin, and others.
Dive deep into rich insights for new drugs for Biliary Tract Cancers Treatment, Visit @ Biliary Tract Cancers Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Biliary Tract Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Biliary Tract Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Envafolimab: Alphamab Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SMT-NK: SMT bio Co., Ltd.
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. HA121-28: CSPC ZhongQi Pharmaceutical Technology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. ZKAB001: Lee's Pharmaceutical Limited
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Biliary Tract Cancer Key Companies
24. Biliary Tract Cancer Key Products
25. Biliary Tract Cancer- Unmet Needs
26. Biliary Tract Cancer- Market Drivers and Barriers
27. Biliary Tract Cancer- Future Perspectives and Conclusion
28. Biliary Tract Cancer Analyst Views
29. Biliary Tract Cancer Key Companies
30. Appendix
For further information on the Biliary Tract Cancers Pipeline therapeutics, reach out to Biliary Tract Cancers Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biliary Tract Cancers Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight here
News-ID: 3469050 • Views: …
More Releases from DelveInsight Business Research

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…

Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…

Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…

Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…